Scarica l'app Stockscreener
2.295
3.85%
0.085
Precedente Chiudi:
$2.21
Aprire:
$2.21
Volume 24 ore:
167.42K
Relative Volume:
0.81
Capitalizzazione di mercato:
$6.98M
Reddito:
$895.50K
Utile/perdita netta:
$-26.30M
Rapporto P/E:
-1.3994
EPS:
-1.64
Flusso di cassa netto:
$-23.84M
1 W Prestazione:
-7.09%
1M Prestazione:
-28.73%
6M Prestazione:
-74.39%
1 anno Prestazione:
-90.72%
Intervallo 1D:
$2.08
$2.34
Intervallo di 1 settimana:
$2.08
$2.50
Portata 52W:
$2.08
$40.40
Mainz Biomed N V Stock (MYNZ) Company Profile
Nome
Mainz Biomed N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta MYNZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
2.295 | 7.72M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
411.40 | 163.30B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.01 | 143.73B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
515.27 | 40.98B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.25 | 32.94B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
144.02 | 27.01B | 15.50B | 1.33B | 2.16B | 7.34 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Maxim Group | Buy |
| 2024-11-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | Iniziato | H.C. Wainwright | Buy |
Mainz Biomed N V Borsa (MYNZ) Ultime notizie
Mainz Biomed (MYNZ) Prices $4M Follow-On Offering - GuruFocus
Maxim Group to Act as Sole Placement Agent for MYNZ Offering | M - GuruFocus
Mainz Biomed Announces Pricing of $4 Million Follow-On Offering and Warrant Amendments - Nasdaq
Cancer Detection Company Mainz Biomed Raises Fresh $4M: Key Details of Share and Warrant Offering - Stock Titan
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants - GlobeNewswire
Mainz Biomed stock plunges to 52-week low of $2.18 amid market challenges - Investing.com
Trend Tracker for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed to update on CRC screening study by end of summer - Investing.com South Africa
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Mainz Biomed Plans Interim Readout For EAArly DETECT 2 CRC Study - Nasdaq
Revolutionary Cancer Prevention: Mainz Biomed Combines AI and mRNA in 2,000-Patient Colorectal Screening Trial - Stock Titan
Mainz Biomed to hold annual meeting on June 2 - Investing.com Australia
Mainz Biomed to hold annual meeting on June 2 By Investing.com - Investing.com Canada
Mainz Biomed Prepares for June 2025 Annual General Meeting - TipRanks
Stocks of Mainz Biomed N.V (MYNZ) are poised to climb above their peers - Sete News
Investing in Mainz Biomed N.V (MYNZ): What You Must Know - knoxdaily.com
Mainz Biomed Enters into Technology Partnership with EDX Medical Group - MSN
MYNZ Partners with EDX Medical to Enhance Diagnostic Offerings i - GuruFocus
Strategic Partnership: Mainz Biomed and EDX Medical Join Forces to Transform Early Cancer Detection in UK Market - Stock Titan
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for Co - GuruFocus
Mainz Biomed N.V (NASDAQ: MYNZ) Is Expected To Soar To Higher Prices In The Months To Come. - Marketing Sentinel
Mainz Biomed advances in FDA approval for CRC test By Investing.com - Investing.com South Africa
Mainz Biomed advances in FDA approval for CRC test - Investing.com Australia
The Mainz Biomed N.V (MYNZ) Stock Is Headed for a Correction - uspostnews.com
MYNZ: Mainz Biomed Advances Cancer Detection with New Feasibilit - GuruFocus
Mainz Biomed N.V. Reports Q1 2025 Accomplishments and FDA Premarket Approval Progress - Nasdaq
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval - GlobeNewswire
Mainz Biomed's Game-Changing Cancer Test Shows 98% Accuracy as Company Expands European Presence - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Short Interest Down 48.7% in April - Defense World
Mainz Biomed (MYNZ) Sees Revenue Surge Amid Strong Demand for ColoAlert - GuruFocus
Long Term Trading Analysis for (MYNZ) - news.stocktradersdaily.com
Mainz Biomed (NASDAQ:MYNZ) Trading Up 3.9% – What’s Next? - Defense World
Colorectal to Pancreatic: Mainz Biomed Expands Reach in Early Cancer Detection - Markets Herald
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - ADVFN
(MYNZ) Investment Report - news.stocktradersdaily.com
Mainz BioMed's Trial To Bring Critical Early Cancer Detection One Step Closer - Benzinga
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Mainz Biomed Reports 2024 Financial Success and Strategic Advances - TipRanks
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Virtu Financial LLC Takes $79,000 Position in Mainz Biomed (NASDAQ:MYNZ) - Defense World
Mainz Biomed (MYNZ) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Mainz Biomed begins pivotal colorectal cancer test study By Investing.com - Investing.com Canada
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - The Manila Times
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - Stock Titan
Mainz Biomed N V Azioni (MYNZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):